Medherant is a clinical-stage company developing innovative treatments for pain and CNS diseases using its novel transdermal drug delivery technology, the TEPI Patch®. There is considerable interest in the transdermal delivery of drugs to overcome some of the disadvantages of oral administration, such as spikes in drug levels that can lead to side effects, and poor compliance. Patches are also a more convenient way to deliver drugs through the skin than gels and creams and provide better dose control.

TEPI patch technology

The Company was founded by Professor David Haddleton and the University of Warwick using their world-leading expertise in bioadhesives and polymer chemistry.

Medherant has an exclusive worldwide licence to a novel, revolutionary, pressure sensitive adhesive developed by Bostik. The drug to be delivered is mixed with the adhesive.

Medherant is developing its own TEPI Patch products which is intends to license for commercialisation.  Phase I clinical studies with the first product have shown that the novel adhesive is well-tolerated. Medherant is also collaborating with third parties to formulate their drugs for transdermal delivery and expects to receive its first licence revenues in 2019.

Medherant has secured funding from Mercia Fund Management and private investors.